Localized Osteosarcoma in Upper Egypt: A Clinical Prediction Model

Status Completed

Clinical Trial Summary

To assess survival outcome of pediatric patients with localized osteosarcoma of the extremities in Upper Egypt, identify factors of prognostic significance for survival, and to determine factors predictive of surgical methods employed in these patients, and developing a clinical model for risk prediction.

Clinical Trial Description

Background Osteosarcoma is the most common of all primary malignant bone tumors. Accounting for about 2.6% of all pediatric neoplasms, it predominantly occurs in the extremities, with a peak incidence in the second decade of life.

In Upper Egypt, we have a higher proportion of the population in underdeveloped communities with limited access to medical care so the patients usually seek medical advice at advanced stage leading to a higher prevalence of metastatic disease at initial presentation, as well as a greater proportion of larger tumor size that more likely to be associated with potential adverse risk criteria prior to surgery.

A previous study from Upper Egypt showed that a metastatic disease at diagnosis was independently correlated to a dismal outcome. Since the effect of many other factors of prognostic significance, such as, gender, age, tumor location and response to chemotherapy may have been mitigated by the large effect of the metastatic disease on the prognosis; So, here, we will analyze the data of 30 patients with non-metastatic osteosarcoma of the extremities, to determine prognostic factors associated with survival, and also to develop a model for a better prediction of factors correlated to that a certain surgical approach was employed in these patients based on their baseline clinical data and the tumor response to chemotherapy.

Patients & Methods We will carry out a retrospective analysis of data assembled from medical records of 30 pediatric patients with a histologically-verified non-metastatic osteosarcoma of the extremities treated at South Egypt Cancer Institute with a unified chemotherapy protocol between January 2001 and December 2015. These data will be categorized according to demographic data, clinical characteristics, tumor response to chemotherapy, and surgical methods employed in these patients. Prognostic factors will be determined using univariable and multivariable methods. A predictive model for surgical outcomes in these patients based on the baseline clinical factors, and their tumor response to chemotherapy will be developed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03839095
Study type	Observational
Source	Assiut University
Contact
Status	Completed
Phase
Start date	January 1, 2018
Completion date	August 25, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02303366` - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475	Phase 1
Withdrawn	`NCT00095017` - Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)	Phase 2
Withdrawn	`NCT00851162` - Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions	Phase 2/Phase 3
Completed	`NCT00168129` - Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases	Phase 1
Completed	`NCT04300179` - Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt
Recruiting	`NCT02677961` - An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
Completed	`NCT02557243` - Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study
Completed	`NCT01479283` - Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)	Phase 3
Recruiting	`NCT06335251` - Radiotherapy Treatments for Neoplasms of the Limbs
Completed	`NCT00558272` - Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease	Phase 2
Completed	`NCT00211211` - FREE Study - Fracture Reduction Evaluation	Phase 4
Completed	`NCT02274623` - Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid	Phase 1
Completed	`NCT02107664` - The Palliative Radiotherapy And Inflammation Study - PRAIS
Completed	`NCT00434447` - Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases	Phase 4
Terminated	`NCT00381095` - A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer	Phase 4
Completed	`NCT00909142` - Bonefos and the Consumption of Analgesics	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.